Resources

Publications

12/06/2024
- Oncology
Optimizing Clinical Trial Subject Selection: Insights from Exigent Research Network and the Tempus AI TIME Program Collaboration
AI in Precision Oncology
12/03/2024
- Oncology
Tumor-Derived CCL2 Drives Tumor Growth and Immunosuppression in IDH1-Mutant Cholangiocarcinoma
Hepatology
12/03/2024
- Oncology
Tremelimumab and Durvalumab as Neoadjuvant or Non-Operative Management Strategy of Patients With Microsatellite Instability-High Resectable Gastric or Gastroesophageal Junction Adenocarcinoma: The INFINITY Study by GONO
Annals of Oncology
11/25/2024
- Oncology
Multicenter Retrospective Cohort Study of the Sequential Use of Antibody Drug Conjugates Trastuzumab Deruxtecan & Sacituzumab Govitecan in Patients With HER2 Low Metastatic Breast Cancer: A Subgroup Analysis of Next Generation Sequencing Results.
SABCS 2024
11/25/2024
- Oncology
A Phase II Study of Pembrolizumab Plus Fulvestrant in ER Positive, HER2 Negative Advanced/Metastatic Breast Cancer Patients
SABCS 2024
11/25/2024
- Oncology
Economic Impact of Concurrent Tissue and Circulating Tumor DNA Molecular Profiling in Advanced Breast Cancer Patients
SABCS 2024
11/25/2024
- Oncology
Real-World Clinical Outcomes of Patients With HER2- BRCAm Early Breast Cancer Treated With Adjuvant Capecitabine
SABCS 2024
11/25/2024
- Oncology
Real-World Comparative Efficacy of CDK4/6 Inhibitors in First-Line Treatment of HR+/HER2- Metastatic Breast Cancer
SABCS 2024
11/25/2024
- Oncology
Low-Level Aurora Kinase a (Aurka) Amplification as a Novel Personalized Biomarker of CDK4/6 Inhibitor (CDK4/6i) Resistance in Patients With Hormone-Receptor Positive (HR+) Metastatic Breast Cancer
SABCS 2024
11/25/2024
- Oncology
Effects of Socioeconomic Status on Access to Next-Generation Sequencing In Patients With Metastatic Breast Cancer
SABCS 2024

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61